Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

Treatment response is usually assessed by the response evaluation criteria in solid tumors (RECIST). These criteria may not be adequate to evaluate the response to immunotherapy, considering the peculiar patterns of response reported with this therapy. With the advent of immunotherapy these criteria...

Full description

Bibliographic Details
Main Authors: Veronica Mollica, Stefano Brocchi, Filippo Gustavo Dall’Olio, Laura Marcolin, Alexandro Paccapelo, Matteo Santoni, Alessandro Rizzo, Rodolfo Montironi, Rita Golfieri, Francesco Massari, Andrea Ardizzoni
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
renal cell carcinoma
RCC
nivolumab
immunotherapy
tumor growth rate
TGR
Online Access:https://www.mdpi.com/2072-6694/13/14/3492

Internet

https://www.mdpi.com/2072-6694/13/14/3492

Similar Items